Patents Assigned to THESAN PHARMACEUTICALS, INC.
-
Publication number: 20180185325Abstract: The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.Type: ApplicationFiled: June 8, 2016Publication date: July 5, 2018Applicant: Thesan Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Howard Glenn Welgus, Jay Edward Birnbaum, J. Gordon Foulkes, Celia Patricia Jenkinson, Jean Hilaire Saurat
-
Publication number: 20180179174Abstract: The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.Type: ApplicationFiled: June 6, 2016Publication date: June 28, 2018Applicant: Thesan Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Howard Glenn Welgus, Jay Edward Birnbaum, J. Gordon Foulkes, Celia Patricia Jenkinson, Jean Hilaire Saurat
-
Publication number: 20180118707Abstract: The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.Type: ApplicationFiled: June 7, 2016Publication date: May 3, 2018Applicant: Thesan Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Howard Glenn Welgus, Jay Edward Birnbaum, J. Gordon Foulkes, Celia Patricia Jenkinson, Jean Hilaire Saurat
-
Publication number: 20170042856Abstract: The subject invention provides a method of treating acne in a subject which comprises topically and periodically applying to the subject's acne a composition comprising 3-phenyl-benzo[f]chromen-1-one and a pharmaceutically acceptable carrier, wherein the 3-phenyl-1-benzo[f]chromen-1-one is present in an amount effective to treat the subject's acne. The subject invention also provides a method of treating a skin condition associated with abnormal sebum secretion or abnormal sebaceous gland function in a subject, compositions in such methods and a sorting method for identifying agonists of AhR pathway useful in such methods and compositions.Type: ApplicationFiled: October 26, 2016Publication date: February 16, 2017Applicant: Thesan Pharmaceuticals, Inc.Inventor: Jean Hilaire Saurat
-
Patent number: 9480674Abstract: The subject invention provides a method of treating acne in a subject which comprises topically and periodically applying to the subject's acne a composition comprising 3-phenyl-1-benzo[f]chromen-1-one and a pharmaceutically acceptable carrier, wherein the 3-phenyl-1-benzo[f]chromen-1-one is present in an amount effective to treat the subject's acne. The subject invention also provides a method of treating a skin condition associated with abnormal sebum secretion or abnormal sebaceous gland function in a subject, compositions in such methods and a sorting method for identifying agonists of AhR pathway, useful in such methods and compositions.Type: GrantFiled: November 7, 2014Date of Patent: November 1, 2016Assignee: THESAN PHARMACEUTICALS, INC.Inventor: Jean Hilaire Saurat
-
Patent number: 9463182Abstract: The use, as a dermatological or cosmetic ingredient, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization in situ.Type: GrantFiled: November 7, 2014Date of Patent: October 11, 2016Assignee: THESAN PHARMACEUTICALS, INC.Inventor: Jean Hilaire Saurat
-
Patent number: 9358220Abstract: The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.Type: GrantFiled: January 28, 2015Date of Patent: June 7, 2016Assignee: THESAN PHARMACEUTICALS, INC.Inventor: Jean Hilaire Saurat
-
Patent number: 9260450Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: March 3, 2015Date of Patent: February 16, 2016Assignee: THESAN PHARMACEUTICALS, INC.Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 9090625Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: April 17, 2013Date of Patent: July 28, 2015Assignee: THESAN PHARMACEUTICALS, INC.Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 9011885Abstract: The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.Type: GrantFiled: July 30, 2014Date of Patent: April 21, 2015Assignee: Thesan Pharmaceuticals, Inc.Inventor: Jean Hilaire Saurat
-
Publication number: 20150094351Abstract: The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atropy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.Type: ApplicationFiled: November 7, 2014Publication date: April 2, 2015Applicant: THESAN PHARMACEUTICALS, INC.Inventor: Jean Hilaire SAURAT
-
Patent number: 8980936Abstract: The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound.Type: GrantFiled: July 18, 2013Date of Patent: March 17, 2015Assignee: Thesan Pharmaceuticals, Inc.Inventors: Jin Li, Nicole Lee Kolosko
-
Publication number: 20150057343Abstract: The subject invention provides a method of treating acne in a subject which comprises topically and periodically applying to the subject's acne a composition comprising 3-phenyl-1-benzo[f]chromen-1-one and a pharmaceutically acceptable carrier, wherein the 3-phenyl-1-benzo[f]chromen-1-one is present in an amount effective to treat the subject's acne. The subject invention also provides a method of treating a skin condition associated with abnormal sebum secretion or abnormal sebaceous gland function in a subject, compositions in such methods and a sorting method for identifying agonists of AhR pathway, useful in such methods and compositions.Type: ApplicationFiled: November 7, 2014Publication date: February 26, 2015Applicant: THESAN PHARMACEUTICALS, INC.Inventor: Jean Hilaire SAURAT
-
Publication number: 20140045911Abstract: The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound.Type: ApplicationFiled: July 18, 2013Publication date: February 13, 2014Applicants: THESAN PHARMACEUTICALS, INC.Inventors: Jin LI, Nicole Lee Kolosko